The marriage of growth factor inhibitors and chemotherapy: Bliss or bust?

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1545-1548

  Staal, Stephen ^a   O'Connell, Michael J ^b   Allegra, Carmen J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; DOXIFLURIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GROWTH FACTOR; IRINOTECAN; LAPATINIB; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PROTEIN KINASE B; RAS PROTEIN; SORAFENIB; STAT PROTEIN; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DISEASE COURSE; DNA REPAIR; DRUG ANTAGONISM; DRUG TARGETING; GENE MUTATION; GROWTH INHIBITION; HUMAN; LUNG CANCER; NOTE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RECTUM CANCER; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; RECEPTORS, GROWTH FACTOR;

EID: 63749087499     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.3224     Document Type: Note

References (51)

1. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
2. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515, 2008
3. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166-1169, 2007
4. Liēvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
5. Liēvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
6. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
7. Bokemeyer C, Bondarenko I, Hartmann JT, et al: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 26:178s, 2008 (suppl; abstr 4000)
8. Punt CJ, Tol J, Rodenburg CJ, et al: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC): The CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26:180s, 2008 (suppl; abstr LBA4011)
9. Van Cutsem E, Lang I, D'Haens G, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26:5s, 2008 (suppl; abstr 2)
10. Hecht Jr, Mitchell E, Chidiac T, et al: An updated analysis of safety and efficacy of oxaliplatin (ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Presented at American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2007
11. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
12. Rothenberg ML: CPT-11: An original spectrum of clinical activity. Semin Oncol 23:21-26, 1996
13. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
14. Grem JL: 5-fluorouracil: Forty-plus and still ticking-A review of its preclin- ical and clinical development. Invest New Drugs 18:299-313, 2000
15. Jhawer M, Goel S, Wilson AJ, et al: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68:1953-1961, 2008
16. Scaltriti M, Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 12:5268-5272, 2006
17. Frattini M, Saletti P, Romagnani E, et al: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:11391145, 2007
18. Parsons DW, Wang TL, Samuels Y, et al: Colorectal cancer: Mutations in a signalling pathway. Nature 436:792, 2005
19. Etienne-Grimaldi MC, Formento JL, Francoual M, et al: K-ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyri-midine therapy. Clin Cancer Res 14:4830-4835, 2008
20. Rödel C, Liersch T, Hermann RM, et al: Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:110-117, 2007
21. Koeberle D, Burkhard R, von Moos R, et al: Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 98:1204-1209, 2008
22. Rödel C, Arnold D, Hipp M, et al: Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70:1081-1086, 2008
23. Dupuis O, Vie B, Lledo G, et al: Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: A GERCOR phase II study. Oncology 73:169-176, 2007
24. Machiels JP, Sempoux C, Scalliet P, et al: Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 18:738-744, 2007
25. Fisher B, Redmond C, Brown A, et al: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4:459-471, 1986
26. Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7:710-717, 1989
27. Albain KS, Green SJ, Ravidin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 143)
28. Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439-3460, 1998
29. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2. Oncogene 18:2241-2251, 1999
30. Pegram MD, Konecny GE, O'Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004
31. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y: Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine. Cancer Chemother Pharmacol 49:211-216, 2002
32. Von Minckwitz G, Vogel P, Schmidt M, et al: Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer. Breast Cancer Res Treat 106, 2007 (suppl; abstr 4056)
33. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008
34. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22:777-784, 2004
35. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794, 2004
36. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chem-otherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
37. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva lung cancer investigation trial. J Clin Oncol 25:1545-1552, 2007
38. Scagliotti G, von Pawel J, Reck M, et al: Sorafenib plus carboplatin/ paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer: Interim analysis results from the phase III randomized, double-blind, placebo-controlled, ESCAPE trial. J Thoracic Oncol 3:1s, 2008 (suppl; abstr 2750)
39. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005
40. Solit DB, She Y, Lobo J, et al: Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 11:19831989, 2005
41. Mahaffey CM, Davies AM, Lara PN Jr, et al: Schedule-dependent apopto- sis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: Rationale for pharmacodynamic separation. Clin Lung Cancer 8:548-553, 2007
42. Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456, 2008
43. Sutherland RL, Green MD, Hall RE, et al: Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0. Eur J Cancer Clin Oncol 19:615-621, 1983
44. Peng D, Fan Z, Lu Y, et al: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56:3666-3669, 1996
45. Lenferink AE, Busse D, Flanagan WM, et al: ErbB2. Cancer Res 61:65836591, 2001
46. Ling YH, Li T, Yuan Z, et al: Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1. Mol Pharmacol 72:248-258, 2007
47. Pegram MD, Slamon DJ: Combination therapy with trastuzumab (hercep- tin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. Semin Oncol 26:89-95, 1999
48. Vigneron A, Gamelin E, Coqueret O: The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomer-ase I inhibition. Cancer Res 68:815-825, 2008
49. Van Schaeybroeck S, Karaiskou-McCaul A, KellyD, et al: Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 11:7480-7489, 2005
50. Johnson DH: Targeted therapies in combination with chemotherapy in non-small-cell lung cancer. Clin Cancer Res 12:4451s-4457s, 2006
51. Milano G, Spano J, Leyland-Jones B: EGFR-targeting drugs in combination with cytotoxic agents: From bench to bedside, a contrasted reality. Br J Cancer9:1-5, 2008